A novel strategy involves combining antibody-drug conjugates (ADCs) with PARP inhibitors. This approach could potentially overcome the need for a germline BRCA mutation, significantly broadening the patient population that could benefit from PARP inhibitor therapy in triple-negative breast cancer.

Enzalutamide's selection was rooted in early pharmacokinetic data showing it decreased talazoparib levels, necessitating a specific dose adjustment. This scientific rationale preceded the clinical belief, also held by the investigator, that enzalutamide is a more effective drug than its alternative, abiraterone.

For high-risk early-stage breast cancer patients with a germline PALB2 mutation, clinicians would consider using an adjuvant PARP inhibitor off-label. This is justified by PALB2's biological similarity to BRCA2 and promising response data from the metastatic setting, providing an option for patients who meet Olympia trial criteria but have a different mutation.

Not all DNA damage repair gene alterations create PARP inhibitor sensitivity. Clinical data from multiple trials (TRITON, PROfound, TALAPRO-2) consistently shows that while BRCA1/2 mutations confer significant benefit, alterations in genes like ATM and CHEK2, which are not core to homologous recombination repair (HRR), do not.

The BREAKAWAY trial's OS data is from a small, crossover-allowed study, making it hard to interpret alone. However, its findings are believable because they align with and reinforce a "building body of evidence" from larger trials like PROPEL and TALA PRO 2, which also show a survival benefit for PARP inhibitor combinations.

While benefit from PARP inhibition is typically confined to core HRR genes like BRCA, the TALAPRO-2 study revealed a distinct signal for patients with CDK12 mutations. This non-canonical finding suggests a different mechanism of sensitivity and identifies a new, albeit small, patient population that may benefit from a talazoparib-enzalutamide combination.

The observed interim overall survival hazard ratio of 0.76 is encouraging but not definitive. Experts caution that such early signals often represent the peak benefit, which can diminish over time as control group patients receive other effective treatments post-progression, making final statistical significance uncertain.

In high-risk, BRCA-positive patients eligible for both, clinicians favor giving a PARP inhibitor first. The rationale is based on established survival data, shorter one-year duration, and emerging biological evidence suggesting BRCA2-mutated tumors may be resistant to CDK4/6 inhibitors due to concurrent RB gene loss.

The initial broad enthusiasm for PARP inhibitors in ovarian cancer has been refined. New data confirms a lack of overall survival improvement for patients with HRD-negative (or HR proficient) tumors, pushing clinicians toward a precision medicine approach where these drugs are reserved for patients with BRCA mutations or HRD-positive disease who are most likely to benefit.